Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
GLP-1
Biotech
Corxel touts ‘competitive’ ph. 2 results for oral GLP-1 asset
With a balance of competitive efficacy and tolerability, Corxel figures it has a potential winner to take into late-stage development.
Eric Sagonowsky
Jun 23, 2026 8:00am
Fierce Pharma
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
Jun 11, 2026 7:00am
GLP-1s may combat depression through a mood-boosting gut microbe
Jun 10, 2026 11:00am
ADA: AZ’s oral GLP-1 shows ‘competitive efficacy’ in phase 2
Jun 9, 2026 9:48am
ADA: Tolerability questions linger for Boehringer's obesity drug
Jun 8, 2026 4:30am
ADA: Lilly offers deeper glimpse into triple-G obesity candidate
Jun 6, 2026 3:28pm
